Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

23 Jun 2021

Abstract excerpt

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34201767
DOI: 10.3390/v13071211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesPMID 34201767Read ↗

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity Read ↗

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read ↗

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read ↗

Convalescent plasma therapy in immunocompromised patients infected with the BA.1 or BA.2 Omicron SARS-CoV-2Semantic proximity Read ↗

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic StrategiesSemantic proximity Read ↗

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read ↗

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read ↗

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B CellsSemantic proximity Read ↗

Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and Neutralizing Antibodies Against SARS-CoV-2 VariantsSemantic proximity Read ↗

Emerging SARS-CoV-2 Variant B.1.1.7 Reduces Neutralization Activity of Antibodies Against Wild-Type SARS-CoV-2Semantic proximity Read ↗

Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineageSemantic proximity Read ↗

Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.